Enoxaparin Management for High‑Risk ERCP with Sphincterotomy

Risk Classification of ERCP

ERCP with sphincterotomy, large‑balloon papillary dilation, or ampullectomy is classified as a high‑risk bleeding procedure by the British Society of Gastroenterology and the European Society of Gastrointestinal Endoscopy. 1
ERCP that involves only biliary or pancreatic stenting (no sphincterotomy) is considered low‑risk for bleeding. 1

Standard timing: Discontinue therapeutic‑dose enoxaparin 12–24 hours before a high‑risk ERCP (e.g., with sphincterotomy). This interval allows sufficient drug clearance while limiting thrombotic risk. 4
Primary therapeutic dosing: For patients receiving enoxaparin as their main anticoagulant, the same 12–24 hour hold is recommended. 4
Bridge therapy for warfarin: When enoxaparin is used as a bridge to warfarin, hold it for 12–24 hours and consider switching to unfractionated heparin per institutional protocol if continuous anticoagulation is required. 4

In individuals with mechanical mitral valves, recent coronary‑artery stents, or atrial fibrillation with mitral stenosis, anticoagulation interruption should be coordinated with cardiology; transition to unfractionated heparin (which can be stopped closer to the procedure) may be necessary. 1

For high‑risk ERCP with sphincterotomy, restart enoxaparin 48–72 hours post‑procedure once adequate hemostasis is confirmed, favoring the longer interval to reduce post‑procedural bleeding. 1
Verify that hemostasis is satisfactory before restarting anticoagulation. 3
The timing of resumption should be discussed with the performing endoscopist. 1

Do not continue therapeutic‑dose enoxaparin through ERCP with sphincterotomy; this markedly raises bleeding risk without providing meaningful thrombotic protection during the brief interruption. 1
Avoid LMWH bridging in patients at low thrombotic risk, as it increases bleeding complications without decreasing thrombotic events. Bridging should be reserved for truly high‑risk patients (e.g., mechanical mitral valve, recent drug‑eluting stent <12 months, bare‑metal stent <1 month). 1